跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PCDH19
首页
药物
PCDH19
PCDH19
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
THERAPEUTIC STRATEGY FOR PCDH19-RELATED ENCEPHALOPATHY
申请人: UNIV LELAND STANFORD JUNIOR
优先权: 2023
EP
WO
2 件公开
COMPOUNDS AND METHODS FOR REDUCING PCDH19 EXPRESSION
申请人: IONIS PHARMACEUTICALS INC
优先权: 2021
EP
US
2 件公开
Compositions and methods for treating PCDH19 related conditions
申请人: FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH
优先权: 2022
CN
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PCDH19 RELATED DISORDERS
申请人: THE FLOREY INST OF NEUROSCIENCE AND MENTAL HEALTH
优先权: 2022
US
Diagnostic and therapeutic methods for EFMR (epilepsy and mental retardation limited to females)
申请人: DIBBENS LEANNE MICHELLE
优先权: 2009
US
3 件公开
METHODS OF TREATING X-LINKED GENETIC DISEASES
申请人: YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD
优先权: 2023
US
TREATMENTS FOR CANCERS UTILIZING CELL-TARGETED THERAPIES AND ASSOCIATED RESEARCH PROTOCOLS
申请人: FRED HUTCHINSON CANCER CENTER
优先权: 2022
US
USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES
申请人: GW RES LTD
优先权: 2020
EP
US
WO
3 件公开
药物
反馈